Cornercap Investment Counsel Inc Catalyst Pharmaceuticals, Inc. Transaction History

Cornercap Investment Counsel Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	SELL	$13.18 - $17.11 $15,433 - $20,035	-1,171 Reduced 8.75%	12,216 $194,000
Q4 2023 Jan 30, 2024	SELL	$11.78 - $17.29 $869,199 - $1.28 Million	-73,786 Reduced 84.64%	13,387 $225,000
Q3 2023 Nov 13, 2023	BUY	$11.69 - $15.02 $361,665 - $464,688	30,938 Added 55.02%	87,173 $1.02 Million
Q1 2023 May 11, 2023	SELL	$14.34 - $21.05 $246,404 - $361,702	-17,183 Reduced 23.4%	56,235 $932,000
Q4 2022 Feb 13, 2023	SELL	$12.25 - $19.5 $116,583 - $185,581	-9,517 Reduced 11.48%	73,418 $1.37 Million
Q3 2022 Nov 14, 2022	SELL	$7.06 - $15.52 $473,895 - $1.04 Million	-67,124 Reduced 44.73%	82,935 $1.06 Million
Q2 2022 Aug 15, 2022	BUY	$6.23 - $8.57 $16,465 - $22,650	2,643 Added 1.79%	150,059 $1.05 Million
Q1 2022 May 10, 2022	SELL	$5.31 - $8.31 $57,273 - $89,631	-10,786 Reduced 6.82%	147,416 $1.22 Million
Q4 2021 Feb 14, 2022	SELL	$5.21 - $7.45 $301,877 - $431,667	-57,942 Reduced 26.81%	158,202 $1.07 Million
Q3 2021 Nov 15, 2021	BUY	$4.85 - $6.04 $1.05 Million - $1.31 Million	216,144 New	216,144 $1.15 Million

326

94.6M

19.1K

51.1K

Ticker CPRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 102,820,000
Market Cap $2.12B
Description
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...

Get notified when there are updates to the investment portfolio of Cornercap Investment Counsel Inc, based on Form 13F filings with the SEC.

Stay updated on Cornercap Investment Counsel Inc with notifications on news.